{
    "clinical_study": {
        "@rank": "35025", 
        "arm_group": {
            "arm_group_label": "LentiGlobin\u00ae BB305 Drug Product", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a non randomized, open label, multi-site, single-dose, Phase 1/2 study in up to 15\n      adults with beta-thalassemia major. The study will evaluate the safety and efficacy of\n      autologous hematopoietic stem cell transplantation (HSCT) using LentiGlobin\u00ae BB305 Drug\n      Product [autologous CD34+ hematopoietic stem cells transduced with LentiGlobin\u00ae BB305\n      Lentiviral Vector encoding the human \u03b2-A(T87Q)-globin gene]."
        }, 
        "brief_title": "A Study Evaluating the Safety and Efficacy of the LentiGlobin\u00ae BB305 Drug Product in Beta-Thalassemia Major Subjects", 
        "condition": "Beta-thalassemia Major", 
        "condition_browse": {
            "mesh_term": [
                "Beta-Thalassemia", 
                "Thalassemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subject participation for this study will be 2 years. Subjects who enroll in this study will\n      be asked to participate in a subsequent long-term follow up study that will monitor the\n      safety and efficacy of the treatment they receive for up to 13 years post-transplant."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Adult subjects between 18 and 35 years of age, inclusive, at the time of consent, and\n             able to provide written consent.\n\n          -  Diagnosis of \u03b2-thalassemia major and a history of at least 100 mL/kg/year of pRBCs or\n             \u22658 transfusions of pRBCs per year for the prior 2 years.\n\n          -  Eligible for allogeneic bone marrow transplant.\n\n          -  Treated and followed for at least the past 2 years in a specialized center that\n             maintained detailed medical records, including transfusion history.\n\n        Exclusion criteria:\n\n          -  Positive for presence of human immunodeficiency virus type 1 or 2 (HIV 1 and HIV 2).\n\n          -  A white blood cell (WBC) count <3 \u00d7 109/L, and / or platelet count <100 \u00d7 109/L if\n             not due to hypersplenism.\n\n          -  Uncorrected bleeding disorder.\n\n          -  Any prior or current malignancy or myeloproliferative or immunodeficiency disorder.\n\n          -  Immediate family member with a known or suspected Familial Cancer Syndrome (including\n             but not limited to hereditary breast and ovarian cancer syndrome, hereditary\n             non-polyposis colorectal cancer syndrome and familial adenomatous polyposis).\n\n          -  Receipt of an allogeneic transplant.\n\n          -  Advanced liver disease, including persistent aspartate transaminase (AST), alanine\n             transaminase (ALT), or total bilirubin value >3 \u00d7 the upper limit of normal, liver\n             biopsy demonstrating cirrhosis, extensive bridging fibrosis, or active hepatitis.\n\n          -  Kidney disease with a calculated creatinine clearance <30% normal value.\n\n          -  Uncontrolled seizure disorder.\n\n          -  Diffusion capacity of carbon monoxide (DLco) <50% of predicted (corrected for\n             hemoglobin).\n\n          -  A cardiac T2* <10 ms by magnetic resonance imaging (MRI).\n\n          -  Any other evidence of severe iron overload that, in the Investigator's opinion,\n             warrants exclusion.\n\n          -  Clinically significant pulmonary hypertension, as defined by the requirement for\n             ongoing pharmacologic treatment or the consistent or intermittent use of supplemental\n             home oxygen.\n\n          -  Participation in another clinical study with an investigational drug within 30 days\n             of Screening.\n\n          -  Any prior or current malignancy or myeloproliferative disorder.\n\n          -  Prior receipt of gene therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "35 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01745120", 
            "org_study_id": "HGB-204"
        }, 
        "intervention": {
            "arm_group_label": "LentiGlobin\u00ae BB305 Drug Product", 
            "description": "Transplant of autologous hematopoietic stem cells transduced with LentiGlobin\u00ae BB305 lentiviral vector.", 
            "intervention_name": "LentiGlobin\u00ae BB305 Drug Product", 
            "intervention_type": "Genetic"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "gene therapy", 
            "beta thalassemia", 
            "hemoglobin", 
            "anemia", 
            "CD34"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia"
                    }
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With \u03b2-Thalassemia Major by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral \u03b2-A(T87Q)-Globin Vector (LentiGlobin\u00ae BB305 Drug Product)", 
        "overall_contact": {
            "email": "clinicaltrials@bluebirdbio.com", 
            "last_name": "bluebird bio"
        }, 
        "overall_official": {
            "affiliation": "bluebird bio", 
            "last_name": "Sandeep Soni, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Evaluate the efficacy of treatment with LentiGlobin\u00ae BB305 Drug Product in subjects with \u03b2-thalassemia major as measured by the production of hemoglobin containing the therapeutic globin protein [\u03b2-A(T87Q)-globin]", 
                "safety_issue": "No", 
                "time_frame": "18 - 24 months post-transplant"
            }, 
            {
                "measure": "Evaluate the safety of treatment with LentiGlobin\u00ae BB305 Drug Product in subjects with \u03b2-thalassemia major as measured by the incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "0-24 months post-transplant"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01745120"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Hematopoietic stem cell engraftment", 
                "safety_issue": "Yes", 
                "time_frame": "42 days post-transplant"
            }, 
            {
                "measure": "Assess transgene marking as determined by measurement of the average vector copy number in peripheral blood and bone marrow", 
                "safety_issue": "No", 
                "time_frame": "0 - 24 months post-transplant"
            }
        ], 
        "source": "bluebird bio", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "bluebird bio", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}